Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination.

Gustafsson NMS, Färnegårdh K, Bonagas N, Ninou AH, Groth P, Wiita E, Jönsson M, Hallberg K, Lehto J, Pennisi R, Martinsson J, Norström C, Hollers J, Schultz J, Andersson M, Markova N, Marttila P, Kim B, Norin M, Olin T, Helleday T.

Nat Commun. 2018 Sep 24;9(1):3872. doi: 10.1038/s41467-018-06287-x.

2.

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5.

3.

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. Erratum in: Nat Commun. 2018 May 22;9(1):2071.

4.

Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor.

Gustafsson R, Jemth AS, Gustafsson NM, Färnegårdh K, Loseva O, Wiita E, Bonagas N, Dahllund L, Llona-Minguez S, Häggblad M, Henriksson M, Andersson Y, Homan E, Helleday T, Stenmark P.

Cancer Res. 2017 Feb 15;77(4):937-948. doi: 10.1158/0008-5472.CAN-16-1476. Epub 2016 Nov 29.

5.

The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features.

Hammarström LG, Harmel RK, Granath M, Ringom R, Gravenfors Y, Färnegårdh K, Svensson PH, Wennman D, Lundin G, Roddis Y, Kitambi SS, Bernlind A, Lehmann F, Ernfors P.

J Med Chem. 2016 Sep 22;59(18):8577-92. doi: 10.1021/acs.jmedchem.6b01009. Epub 2016 Sep 8.

PMID:
27607569
6.

Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells.

Zovko A, Novak M, Hååg P, Kovalerchick D, Holmlund T, Färnegårdh K, Ilan M, Carmeli S, Lewensohn R, Viktorsson K.

Oncotarget. 2016 Aug 2;7(31):50258-50276. doi: 10.18632/oncotarget.10361.

7.

Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma.

Zovko A, Viktorsson K, Hååg P, Kovalerchick D, Färnegårdh K, Alimonti A, Ilan M, Carmeli S, Lewensohn R.

Mol Cancer Ther. 2014 Dec;13(12):2941-54. doi: 10.1158/1535-7163.MCT-14-0329. Epub 2014 Oct 15.

Supplemental Content

Loading ...
Support Center